西地那非干预疑诊早期高原肺动脉高压人群的临床研究  

Sildenafil for intervention of suspected early high altitude pulmonary hypertension: a clinical study of 24 cases

作　　者：周正茂[1] 覃军[1] 黄岚[1] 文朝远[2] 谭虎[1] 张玉舟[2] 周音频[1] 魏军义[2] 李子良[2] 

机构地区：[1]第三军医大学新桥医院心血管内科全军心血管病研究所,重庆400037 [2]中国人民解放军第八医院,西藏日喀则857000

出　　处：《第三军医大学学报》2012年第6期485-487,共3页Journal of Third Military Medical University

基　　金："十一五"国家科技支撑计划(2009BAI85B02)~~

摘　　要：目的评价口服西地那非干预疑诊早期高原肺动脉高压(high altitude pulmonary hypertension,HAPH)的有效性及安全性。方法 24例常驻高海拔地区(4 500 m)疑诊早期HAPH的青年男性,分为2组,A组(11例)予以吸氧治疗,B组(13例)予以吸氧+口服西地那非治疗,治疗12周后,观察主要终点6 min步行距离试验(6MWT)及次要终点Brog呼吸困难评分、肺动脉收缩压(SPAP)、血氧饱和度及受试者的血压、肝肾功变化情况。结果①经12周治疗后,B组6MWT从(405.54±42.40)m增加至(463.34±40.12)m(P<0.05),A组6MWT从(407.53±50.14)m增加至(444.53±56.36)m(P<0.05),B组比A组增加更明显(P<0.05);Brog呼吸困难评分2组均明显改善(P<0.05),B组比A组改善更明显(P<0.05);B组SPAP由(25.56±1.85)mmHg降低到(21.69±1.88)mmHg(P<0.05),A组SPAP由(26.25±1.25)mmHg降低到(25.27±1.10)mmHg;B组比A组明显降低(P<0.05)。②服药前后,受试者血压及肝、肾功能无明显变化。结论口服西地那非(50 mg,1次/d)干预疑诊早期HAPH人群是安全和有效的。Objective To evaluate the efficacy and safety of oral administration of sildenafil on the treatment of suspected early high altitude pulmonary hypertension（HAPH）.Methods After a cohort of young males living above 4 500 m screened by medical examination,24 subjects were diagnosed as suspected early HAPH,and enrolled in this study.These subjects were randomly divided into 2 groups,Group A（n=11） who receiving supplemental oxygen,and Group B（n=13） who were treated with oxygen supplement combined with oral taking of 50 mg sildenafil per day for 12 weeks.The subjects were followed-up by telephone.At the end of treatment,6-minute walk test（6MWT）,Borg dyspnea scores,systolic pulmonary arterial pressure（SPAP）,percutaneous oxygen saturation,blood pressure,liver function and kidney function were used to evaluate the efficiency.Results After 12 weeks＇ intervention,6MWT in group A was improved from（407.53±50.14） m to（444.53±56.36） m（P0.05）,and that in group B was improved from（405.54±42.40） m to（463.34±40.12） m（P0.05）,with the later was obviously improved more than the former（P0.05）.Borg dyspnea scores of 2 groups were also obviously improved than before treatment（P0.05）,and still that in group B was obviously improved greater than that in group A（P0.05）.SPAP in group A was decreased from（26.25±1.25） mmHg to（25.27±1.10） mmHg（P0.05）,and that in group B decreased from（25.56±1.85） mmHg in the baseline to（21.69±1.88） mmHg（P0.05）.Group B was obviously decreased more than group A（P0.05）.There was no obvious side effect and change in blood pressure,liver function and kidney function in sildenafil treatment.Conclusion Oral administration of sildenafil is an efficient and safe intervention for suspected early HAPH.

关 键 词：西地那非 高原肺动脉高压 有效性 安全性 

分 类 号：R544.105[医药卫生—心血管疾病] R972.4[医药卫生—内科学]